Juvmo (tavapadon) for Adult Parkinson’s: D1/D5 Partial Agonist, Once Daily, Monotherapy or Adjunct to Levodopa

　　1.Mechanism and Position

　　Juvmo(tavapadon,originally Cerevel,now AbbVie)selectively engages dopamine D1/D5 receptors as a partial agonist,with less reliance on D2/D3 dominance.D1/D5 signaling in striatal direct pathways supports movement initiation,rigidity reduction,and bradykinetic improvement.Partial agonism plus D1/D5 selectivity may reduce some dopaminergic adverse effects versus older D2/D3 full agonists,but it does not stop nigral degeneration.

　　It is symptomatic only,not disease‑modifying;for adults,not children,and not a replacement for levodopa,MAO‑B/COMT strategy,or DBS evaluation.

　　2.Indication and Dosing

　　Early Parkinson without systematic levodopa:monotherapy,individualize 5–15mg once daily by motor burden,age,and tolerance.

　　Levodopa with wearing‑off or off periods:add tavapadon 5–15mg once daily;re‑evaluate total levodopa for on‑time,dyskinesia,and hypotension rather than self‑adjusting.

　　Administration:once‑daily oral,with or without food;lower starting doses suit older patients,orthostatic history,or cognitive impairment.Missed dose:take per label same day or skip;never double.

　　Titration in 5mg steps within 5–15mg;reduce or hold for intolerable somnolence,vertigo,hallucinations,marked orthostatic hypotension,or dyskinesia,then review in a movement disorders clinic.

　　3.Key Trial Evidence

　　TEMPO program supported approval:

　　TEMPO‑1:randomized,double‑blind,placebo‑controlled early untreated patients;primary MDS‑UPDRS Part II(activities)plus Part III(motor).Tavapadon reduced combined scores versus placebo at fixed 5mg and 15mg,supporting monotherapy startup.

　　TEMPO‑2:flexible 5–15mg once daily in early patients;at 26 weeks combined motor/daily scores improved versus placebo,with higher patient global impression response;common events were nausea,headache,dizziness,mostly mild‑moderate and dose‑related.

　　TEMPO‑3:stable levodopa with motor fluctuations;add tavapadon 5–15mg or placebo.Home Hauser diary showed on‑time without troublesome dyskinesia about 1.7 vs 0.6 hours and greater off‑time reduction;adjunct common events included nausea,dyskinesia,dizziness,headache,hallucinations,orthostatic hypotension.

　　Caveat:TEMPO was largely placebo‑controlled,not full head‑to‑head against all marketed dopamine agents;choice of monotherapy,adjunct,or switching from D2/D3 agonists depends on age,cognition,impulse risk,hypotension,dyskinesia,and levodopa load.

　　4.Safety and Alarm Signs

　　Common:nausea,dizziness,headache,fatigue,insomnia,constipation;with levodopa,increased dyskinesia.

　　Key warnings:

　　Orthostatic hypotension:standing dizziness,presyncope,falls;start low,assess fluids and antihypertensives,measure lying/standing blood pressure.

　　Somnolence and sudden sleep episodes:avoid driving/operating machinery until response is known;if sudden sleep occurs,stop driving and taper/adjust.

　　Psychosis:hallucinations,delusions,confusion—more likely with cognitive impairment,older age,or combined sedating/anticholinergic/dopaminergic drugs.

　　Impulse control disorders:pathological gambling,shopping,sexual behavior,binge eating;D1/D5 partial agonism can still precipitate these,so caregivers should report behavior changes.

　　Dyskinesia:involuntary writhing,head/trunk movements when adjunct to levodopa;record timing and impact,then adjust tavapadon and/or levodopa.

　　Other urgent issues:palpitations with dehydration,depressed mood/suicidal ideation,severe GI intolerance.

　　5.Management Boundaries

　　Goal is symptom control,daily function,and quality of life,not maximal dosing.Follow MDS‑UPDRS,on/off diaries,cognition/mood screens,orthostatic blood pressure,and fall risk.Advanced cases combine rehabilitation,speech/nutrition,bladder/bowel care,and,when fluctuations/dyskinesia dominate,movement‑disorder center review for DBS or continuous infusion.Juvmo adds a D1/D5 mechanism option within individualized Parkinson care.